Since 1985, when the first studies with stem cell gene transfer were reported, we have been tantalized by the possibilities of gene therapy. It at once captivates us with the promise of curing a vast array of inherited, malignant and even infectious diseases, and challenges us with feasibility, safety and ethical considerations. In both the preclinical and clinical studies, gene therapy studies has also taught us a great deal about stem cell transplant biology.
Gene therapy attracted somewhat premature enthusiasm in the mid-1980s, as a targeted and permanent treatment for many previously incurable disorders. However, the field has met with more clinical disappointment than success until very recently. Early results raised more questions than they answered and helped to focus attention on the elusive prerequisites of identifying an appro priate target cell, establishing efficient transfer of the therapeutic gene maintaining stable integration and expression of the gene and understanding and explaining the risks involved.
Bone marrow derived stem cells
Hematopoietic stem cells are arguably the most attractive and best-studied target cell population for several reasons. They are easily accessible for harvest, and readily delivered back to the patient by autologous transplant methods that are already familiar and commonplace to transplant physicians. They are long-lived, and have an enormous repopulation potential. Furthermore, they are pluripotent and hold the potential to correct defects in all hematopoietic lineages, and even nonhematopoietic cell lines via transdifferentiation.
Drawbacks of using hematopoietic stem cells as targets include historically low rates of successful transduction, given their lack of cell surface receptors and quiescent state. Also, identification of the ideal stem cell has proven elusive. In most clinical gene therapy trials, CD34+ cells are isolated from blood or marrow using immunomagnetic selection and transduced. However, evidence suggests there are CD34À cells that possess the properties of stem cells 1, 2 and that even a single CD34À cell is capable of long-term repopulation of hematopoiesis. 3 Finally, CD34 has been shown to be expressed reversibly on murine stem cells. 4 Better identification of the true hematopoietic stem cell, which appears to be modulated by age, cytokine activation, cell cycle state and purification technique, as well as attention to the accessory cells used in the transplantation protocol, may improve transduction efficiency and clinical results in the future.
Other bone marrow-derived cell types of interest include mesenchymal stem cells and multipotent adult progenitor cells, or MAPCs. Mesenchymal stem cells isolated from the bone marrow have the ability to differentiate into not only hematopoietic support stroma, but osteocytes, chondrocytes, tenocytes, adipocytes and skeletal myocytes. In their role as support stroma, mesenchymal stem cells have shown promise in improving the transduction efficiency of hematopoietic stem cells, immuno-downmodulation of graft-vs-host disease after an allograft and potential engraftment. 5, 6 Mesenchymal stem cells also express glucocerebrosidase, alpha-l-iduronidase, arylsulfatases and adrenoleukodystrophy protein, raising the possibility of a therapeutic application in lysosomal storage diseasescharacterized by loss of expression of these proteins, and in other diseases requiring replacement therapy. Although allogeneic bone marrow transplantation has failed to show engraftment of donor mesenchymal stem cells, 7 preclinical models using autologous mesenchymal stem cells and gene transfer have had early success. 8 MAPCs are a unique, newly described class of stem cells, characterized as CD34-, c-kitÀ, HLA-DRÀ, but AC133+, VEGFR2/Flk1/KDR+, and VEGFR1/Flt1+. They have demonstrated a superior proliferative potential with cytogenetic and telomeric stability, while maintaining multipotentiality. They can differentiate in vitro into mesenchymal lineage cells, neural cells, hepatocyte-like cells and angioblasts. 9, 10 A potential application involves early preclinical work using marrow-derived MAPCs to neovascularize infracted myocardium.
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Therapeutic targets
Diseases of hematopoietic stem cells and their progeny are obvious choices for gene therapy. Classically, this has involved providing a therapeutic gene to patients with a single locus genetic deficiency such as any of the genetic disorders that make up severe combined immunodeficiency (SCID), adenosine deaminase (ADA) deficiency, hemoglobinopathies, glycogen storage diseases such as Gaucher's and Hurler's, and disorders of stem cell proliferation such as Fanconi's anemia (Table 1 ). More recently, there has been interest in not just correcting a deficit, but also providing stem cells with new or enhanced properties. This has typically been investigated in the setting of malignant disease. Approaches include chemotherapy resistance genes, and expression of tumor-specific antigens or cytokines to stimulate immune responses against tumors among differentiated progeny such as dendritic cells and lymphocytes. In addition, the ability of hematopoietic stem cells to promote cardiac muscle healing suggests a possible role in the delivery of vascular endothelial growth factor, VEGF. Finally, genetically manipulated hematopoietic stem cells are being pursued as an avenue to provide progeny lymphocytes with resistance to infection, particularly HIV.
Vector choice and design
Gene transfer into hematopoietic stem cells has been demonstrated using many viral and nonviral vectors with varying efficiencies. However, oncoretroviral vectors have been the most widely studied. These vectors are based on simple type C murine oncoretroviruses such as murine leukemia virus. An appealing property of retroviral vectors is that after reverse transcription of their genomic RNA into proviral DNA, it is integrated into the host cell's genome at random locations. This means that all progeny derived from a transduced cell will contain the provirus, and therefore potentially express the therapeutic gene. Hence, an integrating vector is needed when expression of the transgene is required after many cell divisions, such as when a gene needed in terminally differentiated blood cells is transferred to HSC. The oncoretroviral genome is simple in that three genes are encoded. The gag, pol and env genes code for structural, replicative and envelope proteins, respectively. Each end of the integrated provirus contains long terminal repeat (LTR) sequences that have promoter activity for driving the expression of viral genes.
Most current viral gene therapy vectors targeting hematopoietic stem cells are modified in a number of key ways to make them safe for clinical use. First, the vectors are 'gutted' of the endogenous viral genes necessary for viral replication and budding from the cell. Only the genetic information necessary for reverse transcription of the viral RNA into DNA, its subsequent transport to the nucleus and its integration into the genome are retained. Second, the vectors are modified to accept the therapeutic gene. Third, the vectors are modified to enhance expression of the new gene in the target cell and its progeny for many cell generations including many months or years after transplantation. The oncoretroviral vectors have been modified for safety and to carry a therapeutic gene by separating viral functions and the creation of stable virus 'packaging' cell lines that produce virus. Since the virus carries all proteins needed to complete reverse transcription and integration within the virion, no viral coding sequences are required to be transferred to the target cell. To accomplish this, the gag/pol and env genes are separated on plasmids and expressed in trans from a heterologous promoter, while the region between the LTRs, is replaced with the therapeutic gene, also on a plasmid. Since the packaging signal is maintained only on the LTR and therapeutic-gene-containing construct, only it will be packaged, together with the necessary proteins, into virions to be transferred to the target cell. Virus can be produced by transiently transfecting a suitable cell line and collecting culture supernatant or preferably, a packaging line is made by selecting for stably transfected virus-producing cells using selectable genes contained elsewhere on the transfected plasmids. Packaging lines are advantageous in that they and the virus produced can be well characterized for recombination events and consistent virus preparations can easily be obtained. Unfortunately, it has proved quite difficult to transduce human HSC compared to those of animal models, because of the nondividing nature of human HSC and the requirement of division for oncoretroviral vector transduction. 12 For this reason, lentiviral vectors based on the human immunodeficiency virus (HIV) and others have been gaining momentum because they do not require extensive culture and cell proliferation for gene transfer to take place. The most studied HIV-based vector system was originally developed in 1996 by Naldini et al, 13 while concurrently the first demonstration of CD34+ cell transduction using an HIV-based vector was shown by Akkina et al.
14 As required, this vector has been extensively modified to increase safety. HIV is a complex retrovirus and its genome contains nine genes. Of these, four are necessary for in vivo pathogenicity, but dispensable for in vitro propagation. 15 Therefore, safety modifications include the deletion of these four accessory genes and deletion of the wild-type envelope. Packaging, transfer and envelope functions have been delegated to separate plasmids to minimize the generation of replication-competent virus. In addition, a deletion has been made in the viral LTR eliminating its promoter activity, thus requiring an internal promoter. This creates a 'dead' virus upon integration, since transcription cannot begin from the LTR. Production methods still require transient transfection of plasmids for the highest viral production because the envelope, VSV-G and certain HIV proteins are toxic to producer cells. Packaging lines with regulated expression have been developed.
Since cell division is not required for transduction, targeting the true hematopoietic stem cell is potentially more efficient. This has proven to be the case in several studies of human CD34+ cells. [17] [18] [19] Unfortunately, reluctance to consider clinical trials with safety-modified lentivirus, despite their improved efficacy in gene delivery in preclinical models, has delayed the test of their clinical utility. Some of the unknown factors are the capability of the modified vectors to recombine in vivo-either with themselves or with an endogenous virus such as HIV or HTLV -the impact of cell proliferation and differentiation on proviral promiscuity, the potential impact of endogenous transposons and the insertional mutagenesis of the provirus (Tables 2 and 3 ).
Methodological advances in vector delivery
Other methodological advances have significantly improved oncoretroviral gene transfer. One of the primary limitations of clinical retroviral gene transfer studies has been the low gene transfer rates into hematopoietic stem cells, resulting in low frequency and transient detection of transduced cells after reinfusion into the patient. Williams and co-workers 20, 21 found that transduction efficiency could be significantly increased by use of a specific adhesion domain of recombinant fibronectin, CH-296, which colocalizes the viral envelope protein and target cell receptors. Another factor that influences the proliferation rate of hematopoietic progenitors is the nature and the duration of the cytokines used in the ex vivo culture. Addition of thrombopoietin to the combination of stem cell factor and FLT-3 ligand during the transduction period results in an increase in the number of CD34+ progenitors and high levels of engraftment of the transduced human hematopoietic progenitors in immunocompromised mice, compared to previously used combinations. [22] [23] [24] The incorporation of both fibronectin fragment CH-296 and thrombopoietin have proved successful in clinical protocols.
Safety issues
With recent reports in the lay press about severe toxicity and one death in human gene therapy trials, safety considerations have been scrutinized again. Perhaps the largest theoretical concern has been the development of replication-competent viruses. A lymphoma associated with a replication competent retrovirus in a primate model was reported in 1992. 25 The FDA recommendations for monitoring recombinant retrovirus (RCR) in patients include 3 and 6 months, 1 year after treatment and yearly thereafter. If any positive samples are detected, further analysis and extensive patient follow-up is warranted (FDA/CBER Guidance for Industry: Supplemental guidance on testing for RCR in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors, 1999). There have not been any additional reports of RCR since the isolated primate case in 1992. Insertional mutagenesis is believed to account for the abnormal proliferative process seen in a murine model of MDR gene transfer. 26 Two cases of insertional mutagenesis at a locus known to be involved in the pathogenesis of a monoclonal T-cell disorder, similar to an acute lymphocytic leukemia, has been found in children receiving corrective CD34 cell gene therapy for combined variable immunodeficiency (see below), establishing the possibility of this occurring in other stem cell gene therapy settings as well.
Other concerns include immunologic reactions to the transgene product or other components in the gene therapy process. The FDA has also cautioned the use of thrombopoietin because of the potential for induction of immune thrombocytopenia. While this is unlikely since the thrombopoietin remaining in the infusion product is undetectable, platelet counts should be monitored weekly during the first 6 weeks after infusion for safety reasons. Patients receiving cells transduced in the presence of the fibronectin fragment should also be monitored monthly, up to 24 months for formation of antibodies to CH-296. In one recent retroviral gene transfer study, 27 only one of 12 patients had evidence of weakly positive ELISA for antibodies to the protein.
The regulatory oversight for gene therapy trials involves two separate but parallel systems. These are the public review process of the NIH Recombinant DNA Advisory Committee and the regulatory oversight of the Food and Drug Administration. The role of these bodies is to ensure that each study is conducted with clear objectives, rationale and research design, including risks and benefits and detailed methods. Preclinical studies are necessary, including toxicology studies in at least one animal species. 28 
Clinical success
All clinical trials to date have used murine retroviral vectors for transduction. Historically, studies of gene transfer were aimed at transferring a marker gene, rather than a therapeutic gene of interest. In these genetic marking experiments, a gene with an easily detectable sequence or gene product is transferred to autologous cells of patients receiving a therapeutic autograft for an unrelated indication, typically a malignancy. Many of these studies used the neomycin resistance gene, Neo, as the marker, [29] [30] [31] and typically showed detectable but disappointingly low levels of transduction, of less than 5%.
The first clinical trial of therapeutic gene transfer was undertaken in 1990 at the NIH, and enrolled two patients with ADA-deficient SCID. 32 This trial actually targeted peripheral T lymphocytes rather than hematopoietic stem cells. Cells were collected by apheresis, transduced and reinfused several times. One patient demonstrated ADA activity levels up to 25% normal in circulating T cells, which was stable for up to 5 years. The second patient had less encouraging results. A third patient was treated by the same protocol, and again achieved significant levels of ADA activity. 33 Of note, all these patients have continued on PEG-ADA enzyme-replacement; therapy, so the true clinical impact of this success is not known.
In 1992, a study was undertaken in ADA-deficient patients, targeting peripheral lymphocytes with one vector, and bone marrow cells with a slightly different vector. 34 Over time, the dominant detectable vector in peripheral T cells switched from the one used to transduce lymphocytes to the one used to transduce marrow cells. Transduced cells have persisted for several years, and PEG-ADA has been slowly tapered. A study from the Netherlands using CD34+ bone marrow cells reported low efficiency of ADA gene transfer and quite short-lived presence of circulating genetically modified cells. 35 Kohn's group in Los Angeles has treated three neonates with their umbilical cord blood transduced with the ADA gene. Again, persistent but low levels of corrected cells were seen. When enzyme-replacement therapy was tapered, the percentages of marked cells rose to 10%, presumably due to a survival advantage of the corrected cells. 36 The most dramatic success in gene therapy trials has come in the treatment of X-linked SCID. Fischer's group in France reported initial success in two infants in 2000 37 and recently expanded upon their findings, reporting on five patients with up to 2.5 years' follow-up. 38 They collected bone marrow, selected CD34+ cells, performed a supernatant transduction with a retroviral vector containing the common gamma chain gene, and reinfused cells without prior chemoablation. In four of the five patients, transduced T, B and NK cells were persistently detected in the peripheral circulation. T-cell levels recovered from near undetectable to within normal limits, with sustained levels for the duration of follow-up. Furthermore, this translated into a significant clinical benefit with resolution of infectious complications, and other chronic symptoms from the SCID.
Unfortunately, in October 2002, the FDA released information indicating that one, then a second of the 10 children treated, who have now been treated on this trial, had developed a T-cell monoclonal lymphoproliferative disorder culminating in acute lymphocytic leukemia. This process was genotyped and the leukemic cells were found to contain the provirus clonally inserted into the LMO2 site on chromosome 11, commonly associated with a translocation activation of LMO2 in T cell ALL (t 11; 14). Since the classical translocation did not occur, it remains unclear whether the insertion was causative in the leukemia. Wellfounded concerns with all other stem cell gene therapy trials is warranted and all trials on immunodeficient children have been asked to more carefully monitor for monoclonality by the FDA. 39 Whether insertional mutagenesis with clinical consequence is a realistic possibility in other stem cell trials in which cells are infused into hosts with a competent immune system and without the intense pressure for T-cell expansion will unfortunately be an observation that derives from ongoing clinical trials.
In chronic granulomatous disease, five patients received autologous cells transduced with the p47phox gene. 40 Oxidase-positive cells were detected at around 0.1% of circulating neutrophils for up to 12 weeks. However, the effect appeared transient, and it is unclear if stem cells were actually transduced.
After repeated infusions of glucocerebrosidase-transduced peripheral blood stem cells in patients with Gaucher's disease, transduced circulating lymphocytes as well as enzymatic activity were detected for up to several months. 41 Other investigators have been unable to duplicate these results. 42 In addition, Gaucher's disease does not show the classic cross-correction demonstrated by other lysosomal storage diseases, where a small number of normal hematopoietic cells can serve as enzyme donors for many cells of differing lineages. 43 Therefore, it is doubtful that low levels of gene transfer will translate into any significant clinical benefit.
Similarly, when patients with Fanconi anemia complementation group C received transduced autologous cells, corrected circulating leukocytes were detectable for several months, but disappeared by 1 year. 44 Another active area of investigation has been transduction of chemotherapy resistance genes, most notably MDR-1. Several groups have demonstrated the feasibility of transferring the MDR-1 gene, typically in the setting of a myeloablative autologous transplant. [45] [46] [47] Levels of gene marking have typically been less than 5%. More recently, transduction levels of 5-15% of bone marrow progenitor cells, persisting up to 1 year, have been shown using the CD-296 fibronectin fragment during transduction (Table 4) . 27 Transduction has also been shown to translate into a clinical benefit, albeit small. Four patients were transplanted with cells transduced with the MDR gene, then treated with six cycles of paclitaxel. Three demonstrated engraftment of the genetically modified cells. While no enrichment was shown with chemotherapy, there was a correlation between the per cent of granulocytes containing the transgene and the granulocyte nadirs following chemotherapy. 48 In another novel study, the Cowan group at the NIH infused autologous cells into breast cancer patients after ablative chemotherapy, one half of which was incubated with a Neo vector supernatant, and the other half of which was incubated with a MDR vector supernatant. 49 Patients then received chemotherapy with paclitaxel followed by doxorubicin or vinblastine, all known substrates of the pglycoprotein efflux pump encoded by MDR. By semiquantitative PCR, three patients appeared to have stable detection of both genes, while three patients showed enrichment for the MDR gene relative to the neo gene with chemotherapy. This demonstrates for the first time in a human trial that a chemotherapy resistance gene is a selectable and enrichable marker.
At our center, a trial is currently underway investigating the MGMT chemotherapy resistance gene, which protects from alkylation damage. This trial takes advantage of the demonstration that mutations within MGMT render it active for repair of DNA damage but resistant to a clinically used inhibitor, O6-benzylguanine. 50 In preclinical models, selection at the stem cell level in primary and secondary recipient mice is in excess of 1000-fold when the primary recipient does not undergo myeloablation. 51 High levels of expression are sufficient to protect the transduced hematopoietic progenitors from repeated doses of BCNU or temozolomide, rendering the marrow resistant to the chemotherapy. Thus, instead of experiencing cumulative myelosuppression, the marrow is enriched with transduced drug-resistant cells. Should this selection strategy be effective in humans, it might be reasonable to consider using a mutant, O 6 -benzylguanine-resistant MGMT coupled with another gene to transduce hematopoietic stem cells with therapeutic genes, such as those outlined in Table 1 .
Conclusions
Progress has been slow, and gene therapy has not proven to be the cure-all magic bullet promised by the press in early 1980s (Table 5 ). However, progress is being made. Significant advances have occurred in vector design, especially with lentiviral vectors, opening up whole new avenues of possible clinical investigation. Modest improvements in transduction efficiency are made possible with the advent of new cytokines and combinations, and the use of fibronectin. Remaining issues involve optimal expression, stem cell delivery, concerns with insertional mutagenesis and silencing over time that could limit the efficacy of long- With continued scientific endeavor and innovation and further clinical experience, particularly with further development of lentiviral vectors, with their high titers, high transgene expression and maintenance of the stem cell phenotype during transduction, further advances are certain. It is our hope that we are only just beginning to realize the promise of hematopoietic stem cell gene therapy. Targeting repopulating stem cells
